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Objectives: Emergence of multidrug resistance among Streptococcus pneumoniae (SP), has limited the available
options used to treat infections caused by this organism. The objective of this study was to compare the role of
monotherapy and combination therapy with ampicillin (AMP) and azithromycin (AZM) in eradicating bacterial
burden and down regulating lung inflammation in a murine experimental pneumococcal infection model.
Methods: Balb/C mice were infected with 106 CFU of SP. Treatments with intravenous ampicillin (200 mg/kg) and
azithromycin (50 mg/kg) either alone or in combination was initiated 18 h post infection, animals were sacrificed
from 0 – 6 h after initiation of treatment. AMP and AZM were quantified in serum by microbiological assay. Levels
of TNF-α, IFN-γ IL-6, and IL-10 in serum and in lungs, along with myeloperoxidase, inflammatory cell count in
broncho alveolar lavage fluid, COX-2 and histopathological changes in lungs were estimated.
Results: Combination therapy down regulated lung inflammation and accelerated bacterial clearance. This
approach also significantly decreased TNF-α, IFN-γ, IL-6 and increased IL-10 level in serum and lungs along with
decreased myeloperoxidase, pulmonary vascular permeability, inflammatory cell numbers and COX-2 levels in lungs.
Conclusions: Combinatorial therapy resulted in comparable bactericidal activity against the multi-drug resistant
isolate and may represent an alternative dosing strategy, which may help to alleviate problems with pneumococcal
pneumonia.
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InflammationBackground
Streptococcus pneumoniae (SP) is the most frequent iso-
late from clinical samples of respiratory tract infection, in-
cluding acute exacerbation of chronic bronchitis and
community acquired pneumonia (CAP) especially in the
children and elderly [1,2]. Despite the availability of anti-
microbial chemotherapy, the burden of pneumococcal dis-
ease in developing countries has changed very little over* Correspondence: biswadevbishayi4@gmail.com
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reproduction in any medium, provided the orthe last century [3]. The emergence and spread of penicil-
lin resistant strains of SP has been reported from Europe,
Asia, North America and Latin America [4,5] as well as in
India [6]. Moreover an increasing trend in multidrug re-
sistance (such as β-lactams, macrolides, doxycycline, and
recently fluoroquinolone antibiotics) among these penicil-
lin resistant SP has been a major concern worldwide for
clinicians and has complicated the management of CAP
[7,8]. Thus owing to antimicrobial resistance worldwide,
national guidelines recommend a respiratory fluoroquino-
lone or combination antimicrobial therapy for outpatient
treatment of CAP associated with risk factors for drug-
resistant SP but the potential risks associated with thesetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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ical outcome requires further study [9]. The usual first line
antibiotics for bacterial respiratory infections are often
macrolides (azithromycin, clarithromycin or erythromycin)
in case of non-severe infections without risk factors for in-
fection with drug-resistant pathogens, but in case of se-
vere infections and chances of encountering multi-drug
resistant SP, such monotherapy cannot be routinely rec-
ommended. Two of the most widely referenced guidelines
for the management of CAP include those of the Infec-
tious Disease Society of America (IDSA) and the American
Thoracic Society (ATS) which recommends the use of a
fluoroquinolone or a combination of β-lactam and macro-
lide for outpatients as well as for inpatients, non-ICU
treatment [10-14]. Combination antibiotic therapy with
different mechanism of action has been used to treat in-
fections for decades with the goal of producing a wider
spectrum, preventing the emergence of drug resistant sub-
populations, reducing the dose of single agent, and achiev-
ing a synergistic effect. Retrospective studies of patients
with bacteremic pneumonia have suggested that combin-
ation antibiotic therapy is associated with reduced mortal-
ity as compared with that seen among those who receive
monotherapy [15-17]. In addition, most of the retrospec-
tive or observational studies regarding the use of a β-
lactam and macrolide combination in treatment against
pneumococcal bacteremia or CAP showed better outcome
and lower mortality [18-23]. But data comparing the out-
comes of the two most frequently recommended empirical
antibiotic regimens for pneumococcal infection (combin-
ation antibiotic therapy with an extended spectrum β-
lactam and a macrolide) for patients with severe CAP are
sparse [24]. The efficacy and safety of intravenous azithro-
mycin followed by the oral form, given in addition to
intravenous ampicillin –sulbactam, evaluated in patients
hospitalized due to CAP showed that this combination
was effective and well tolerated [25]. It has been reported
that an exposure to drugs such as beta-lactams, can cause
rapid lysis of the Gram-positive bacteria, which leads to
release of proinflammatory bacterial components and
cytotoxins such as pneumolysins [26,27]. These are recog-
nized by the innate immune system, triggering an inflam-
matory burst and potentially exacerbating the ongoing
inflammation. In a model of pneumococcal secondary
bacterial infection in mice, the β-lactam agent ampicillin
was ineffective at reducing mortality despite rapid clear-
ance of bacteria from the lungs [28], but treatment of
mice with azithromycin reduced mortality. Moreover dual
therapy with azithromycin and ampicillin against an azi-
thromycin resistant strain was also able to cure secondary
pneumonia in mice, which was independent of the anti-
bacterial activity of azithromycin [29]. These studies sug-
gested that there might be clinical benefit independent of
antibiotic susceptibility pattern. We hypothesized thatcombination therapy with azithromycin and ampicillin
against an isolate resistant to both the drugs might be able
to exert its bactericidal and anti-inflammatory activities
independent of antibiotic susceptibility pattern. Although
results from in vitro studies are available [30], in vivo stud-
ies must be conducted to confirm the effectiveness of
these combination therapy strategies against isolates re-
sistant to commonly recommended regimens. SP isolates
that were previously examined in human experimental
colonization studies also colonized in inbred adult mice,
thereby demonstrating the relevance of an animal model
of pneumococcal pneumonia [31]. The aim of the present
study was to test the in vivo efficacy of ampicillin and azi-
thromycin alone and in combination against a multi-drug
resistant strain of SP in an experimental murine pneumo-
nia model. Now the question, whether a combination of
ampicillin and azithromycin would be effective in treat-
ment against an isolate of SP non-susceptible to penicillin
and macrolide needs further investigation in vivo. More-
over, studying the experimental pharmacodynamic out-
come associated with the combination therapy and
evaluating the role of the physiological markers of inflam-
mation like the level of proinflammatory (IL-6, TNF-α and
IFN-γ) and anti-inflammatory cytokine IL-10 in the serum
following combination antibiotic therapy, estimating the
myeloperoxidase enzyme activity at the site of infection
(as a marker of tissue neutrophil infiltration) and the level
of expression of cyclooxygenase 2 (COX-2) in the lung
tissue would also help to elucidate the mechanisms re-
sponsible for susceptibility to and pathophysiology of
lung infection and regulation of those markers in
inflammation.
Methods
Antimicrobial agents, media and bacterial strains
The study drugs which included ampicillin (AMP), azi-
thromycin (AZM), amoxicillin/potassium clavulanate
(AMC), oxacillin (OXA), ceftazidime (CAZ), cefotaxime
(CTX), cefuroxime (CXM), ceftriaxone (CRO), clindamycin
(CLI), imipenem (IPM), meropenem (MEM), levofloxacin
(LVX), ciprofloxacin (CIP), rifampicin (RIF), vancomycin
(VAN), trimethoprim/sulphamethoxazole (TMP-SXT), ce-
fepime (FEP) and gentamicin (GEN) (HiMedia, Bombay,
India), were used for all in vitro testing as per Clinical and
Laboratory Standards Institute (CLSI) guidelines and the
same AMP and AZM were used for intravenous injection
in mice. The clinical isolate of S. pneumoniae, AMRI- SP-1,
used for the experiment was obtained from the sputum of
a patient with lower respiratory tract infection, admitted
to Advanced Medicare and Research Institute (AMRI)
hospital in Kolkata, West Bengal, India. A quality control
strain of SP, ATCC 49619 was obtained as a kind gift from
Dr. Indranil Roy, The Calcutta Medical Research Institute
(CMRI), West Bengal, India. The strains were stored in
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(HiMedia, Bombay, India) at -80°C and subcultured twice
onto Columbia blood agar plates (BAP) supplemented
with 5% sheep blood (BioMe’rieux, Lyon, France) over-
night at 37°C in 10% CO2 air incubator before use in all
in vitro and in vivo experiments. All in vitro experiments
were carried out in Mueller Hinton broth (MHB) (HiMe-
dia, Bombay, India). Brain heart infusion broth (BHI)
(HiMedia, Bombay, India) was used as the medium for
pneumococcal cultures prior to experiments with mouse.
All experimental samples were placed on Columbia BAP
(BioMe’rieux, Lyon, France) supplemented with 5% sheep
blood.
In vitro susceptibility tests
Minimum inhibitory concentrations (MICs) and min-
imal bactericidal concentrations (MBCs) were deter-
mined by tube dilution method in MHB supplemented
with 5% sheep blood. The tubes contained two fold dilu-
tions of antibiotics and a final bacterial density of
105 CFU/ml. The tubes were incubated for 18 h at 37°C.
The MIC was defined as the lowest concentration of
antibiotic at which no turbidity was visible to the naked
eye. For determining MBC, 0.01 ml aliquots from tubes
with no visible growth were plated onto BAP supple-
mented with 5% sheep blood and incubated overnight at
37°C. The MBC was defined as the lowest concentration
of antibiotic that killed 99.9% of the original inoculums.
Likewise disk agar diffusion test (DAD) was performed
using Mueller Hinton agar supplemented with 5% sheep
blood. The disk content of each drug, the number of an-
tibiotics tested for MIC and MBC for the clinical isolate
and for the quality control strain ATCC 49619 was done
as per CLSI breakpoints for pneumonia. Modal values
from three separate determinations were taken as the
working values [32,33].
Lung infection model
Male Balb/C mice (25 ± 2 g) were obtained from regis-
tered animal suppliers to the Department. Institutional
Animal Ethical Committee (IAEC) reviewed and ap-
proved the methodology for use of these animals. All an-
imals were maintained and utilized in accordance with
recommendations from the IAEC and were provided
with food and water ad libitum. After overnight incuba-
tion on BHI broth supplemented with 5% sheep blood,
freshly grown colonies were suspended in fresh BHI
broth supplemented with 10% filtered horse serum to an
optical density of 0.12 at 550 nm. Experimental pneumo-
nia was induced in the animals with a penicillin (MIC
64 μg/ml) and macrolide (MIC 8 μg/ml) resistant strain
of S. pneumoniae AMRI-SP-1. Mice were anesthetized
lightly by intravenous injection of ketamine hydrochlor-
ide (Sigma, Life Science) at 1 mg/kg of body weightthrough the tail vein, and 100 μl of a bacterial suspen-
sion (containing approximately 106 colony forming
units) was inoculated through the nares into the lungs of
each mouse (50 μL per nostril). The advantage of intra-
nasal inoculation is to mimic oropharyngeal aspiration,
effectively infects upper and lower respiratory tract and
is very simple. To investigate the change in colony form-
ing units (CFU) in the lungs and blood, animals were
sacrificed under ether anesthesia, from 18th – 24th h post
infection. Blood was collected by cardiac puncture and
their whole lungs were removed aseptically. The lungs
were homogenized in 2 ml of sterile 0.9% saline, and the
homogenates and blood were serially diluted 10-fold
with sterile saline. 100 μL of the diluents of lung homog-
enates as well as blood was spread onto BAP supple-
mented with 5% sheep blood, and the plates were
incubated at 37°C for 24 h. The numbers of CFU were
determined by counting the numbers of single colonies
that appeared on the plates showing alpha hemolysis
(a characteristic specific to S. pneumoniae).
Efficacy as assessed by bacterial density: Determination
of bacterial loads in blood and lungs
Blood (0.5 ml) was obtained at 0 hours (immediately
after administration of the drug), 1, 2, 3, 4, 5, and 6 hours
(18-24 hours post infection) post antibiotic treatment
after AMRI- SP-1 infection by cardiac puncture under
ether anesthesia and exsanguinated at those selected in-
tervals. The blood from each infected mice was diluted
with sterile saline in 1:1 ratio and 100 μl of this diluted
sample was plated on Columbia BAP supplemented with
5% sheep blood. At the previously mentioned time
points post infection, bacterial loads in the lungs of SP
infected mice were determined. For determination of the
numbers of CFU in the lungs, lung tissues were dissected
and homogenized in Hanks’ balanced salt solution with-
out supplements by using a tissue homogenizer. The
resulting homogenates of each sample were then plated in
10-fold serial dilutions on BAP, followed by incubation at
37°C for determination of the bacterial loads, as recently
described in detail [34].
Pharmacokinetic and pharmacodynamic studies
Pharmacokinetic (PK) and pharmacodynamic (PD) studies
were conducted for AMP and AZM in mice. Concentra-
tion in sera was determined after administration through
the tail vein a single intravenous dose of AMP at 200 mg/kg
body weight and AZM at 50 mg/kg body weight. This
dosage of ampicillin and azithromycin produces concen-
trations similar to those achieved in humans after an oral
dose of 500 mg, showing concentrations in pulmonary tis-
sues of mice that were above MIC for the organism for 48
to 72 h after injection. The drugs were administered
through the tail vein in a volume of 100 μL per dose, 18 h
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3, 4, 5 and 6 hours following a single dose of AMP or
AZM or both in combination, blood samples were ob-
tained from the mice in groups of three by cardiac
puncture during ether anesthesia. After blood collec-
tion, samples were centrifuged at 5000 × g at 4°C and
the serum was collected and stored at –80°C until it was
analyzed. Antibiotic concentrations in serum were de-
termined by the agar well diffusion method by using Ba-
cillus subtilis ATCC 12432 as the bioassay reference
strain. The zone diameter obtained were plotted against
known antibiotic concentration comprising a suitable
range on a semi-log graph paper to obtain a standard
curve which was used to extrapolate the antibiotic con-
centration in serum samples at several time points as
stated before. The antibiotic concentration in serum
was then used to assess several PK and PD parameters.
PK parameters assessed were Cmax (μg/ml), defined as
the peak plasma concentration of a drug after adminis-
tration of a dose; Cmin (μg/ml), defined as the lowest
concentration that a drug reaches before the next dose
is administered; area under the concentration curve
(AUC)0-6, an integral of the concentration time curve
(after a single dose or in steady state) measured in
μg.ml−1.h−1; t1/2, defined as the biological half-life,
which is the time required for the concentration of the
drug to reach half of its original value measured in
hours; and ke, defined as the elimination rate constant
which is the rate at which drugs are removed from the
body measured in per hour. Among the PD parameters
assessed were the AUC/MIC ratio, which takes both the
antimicrobial concentration and time into account for
predicting outcomes of concentration independent anti-
biotics, T >MIC, defined as the time period during
which the serum antibiotic concentration remains above
the MIC level measured in hours; Cmax/MIC is the ratio
of maximum achievable concentration of the drug in
serum to MIC.
Protein binding in serum
We have assumed that unbound or free drug equili-
brates with the extravascular space and that the total
concentration of antibiotic in any given space is a com-
bination of the free and protein bound drug has been
considered for binding of protein in serum. Moreover
the actual levels of free drug changes very little with al-
terations in binding to serum proteins of as much as
80% or 90%. Thus the total concentration of antibiotic
in serum has been estimated for studying the in vivo ef-
ficacy of the therapy [36].
Survival rate study
Determination of the efficacy of combination antibiotic
therapy against pneumococcal pneumonia was firstestablished in survival rate studies. Groups of 12 mice
were inoculated intranasaly with S. pneumoniae as de-
scribed above. Treatments with AMP at 200 mg/kg
body weight and AZM at 50 mg/kg body weight either
alone or in combination by intravenous route (through
the tail vein) were initiated 18 hours post infection (p.i.).
Control mice received sterile saline. Survival rate was
recorded every 24 hour until day 3 p.i.
Treatment regimens
18 hours after bacterial inoculation, groups of mice were
treated with a single intravenous dose of either AMP
(200 mg/kg body weight) or AZM (50 mg/kg body
weight) only as monotherapy or administered both as
combination therapy in a 0.1 mL volume, and sacrificed
for sample collection at the previously stated time point,
starting at 18th hours (0 h post antibiotic treatment) and
continuing till 24th h (6 hours post antibiotic treatment)
with an interval of 1 h in between two successive sam-
pling point. Since the aim of the study was to see the
bactericidal activity as will be determined by viable cell
count and not the survival, the endpoint was chosen to
be 6 hours after the initiation of therapy [37]. Mice re-
ceiving combination therapy received 0.1 mL of AMP,
immediately followed by 0.1 mL of AZM. These dosing
intervals were chosen so as to simulate the in vivo effi-
cacy of short term high dose treatment of the drugs in
humans. Untreated SP infected animals were considered
as control and received same volume of isotonic saline
(Additional file 1).
MPO activity as a marker of neutrophil infiltration
Myeloperoxidase (MPO) enzyme activity was analyzed
as index of neutrophil infiltration in the lung tissue, be-
cause it is closely related with the number of neutrophil
present in the tissue. Blood free lung homogenates was
homogenized and centrifuged at 3000 × g for 30 minutes
at 4°C. MPO activity was estimated against a standard
curve made with commercially available MPO, by methods
previously described [38].
Lung vascular permeability
The Evans blue permeability assay was used to quantify
lung capillary permeability. Evans blue avidly binds to
serum albumin and can therefore be used as a tracer for
transcapillary flux of macromolecules. Evans blue (0.2 ml
at a concentration of 25 mg/ml) was injected in a tail vein
30 min prior to the sacrifice. Lungs were homogenized
in 2 ml of potassium phosphate buffer. Evans blue was
extracted by incubating samples in 4 ml of formamide
at 60°C for 24 h, followed by centrifugation at 5,000 × g
for 30 min. The concentration of Evans blue was esti-
mated by dual-wavelength (620 and 740 nm) spectropho-
tometry, which allowed correction of optical densities (E)
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formula was used: E620 (corrected) = E620 - (1.426 ×
E740 + 0.03) [39].
Cytokine levels in lung
For cytokine (IL-6, IL-10, IFN-γ and TNF-α) measure-
ments, lung homogenates were lysed in lysis buffer pH 7.4
consisting of 300 mM NaCl/L, 15 mM TRIS/L, 2 mM
MgCl2/L, 2 mM Triton X-100/L, 20 ng pepstatin A/mL,
20 ng leupeptin/mL, and 20 ng aprotinin/mL, and were
centrifuged at 1500 × g for 15 min at 4°C; the supernatant
was frozen at -20°C, until cytokine measurement by ELISA
as per manufacturer’s protocol (Ray Biotech).
Sample preparation for cytokine measurement from
serum
Blood samples were transferred into micro-centrifuge
tubes and allowed to clot at 4°C followed by centrifuga-
tion at 3000 × g for 5 min at 4°C. The supernatant pale
yellow colored serum was pipette out carefully with the
help of micropipettes into fresh micro centrifuge tubes,
labeled and used for cytokine analysis. Serum from dif-
ferent groups were normalized to the protein content by
Bradford method before the assay and levels of cytokines
(IL-6, IL-10, IFN-γ and TNF-α) were determined by
Sandwich ELISA according to the manufacturer’s in-
struction (Ray Biotech) in a Bio-Rad ELISA Reader.
Expression of Cox-2 in lung tissue
Expression of cyclooxegenase-2 (cox-2) in lung tissues
was determined by immunoblotting by methods described
elsewhere [40].
Inflammatory cells
Leukocyte recruitment to alveoli was determined in the
broncho alveolar lavage fluid (BALF). Briefly, animals
were sacrificed under ether anesthesia and trachea was
exposed and intubated with a catheter, and then re-
peated 1 ml injections of PBS were made until a total of
3 ml of BALF was recovered. BALF was centrifuged at
3,400 × g for 10 min, and supernatant was frozen at -80°C
until analysis of inflammatory mediators. Cells in the
pellet were resuspended in PBS for quantification of leu-
kocytes with a haemacytometer, and cell populations
were enumerated from Diff-Quik Stain kit (Catalog No:
NC9943455; Thermo Fisher Scientific Inc.) cytospin
preparation [41].
Histopathological examinations
Lung injury was observed by standard histological proce-
dures [38]. Whole lungs were fixed in 4% formalin, em-
bedded in paraffin, and processed for light microscopy
using eosin and hematoxylin stainings.Statistical methods
The observers involved in data collection and analysis
were not completely blind to treatment conditions. How-
ever, the methodology used for sample identification pre-
vented subjective bias in the experiments. On the other
hand, doses and animals were randomized to treatment
conditions. Data was expressed as mean ± S.D. Means
were compared between groups by using analysis of vari-
ance (ANOVA). P <0.05 was considered significant.
Results
Determination of MICs, MBCs and DAD for different
antibiotics tested against S. pneumoniae
Median MIC values for different antibiotics against the
isolate AMRI SP-1 and ATCC-49619 were determined
in triplicate according to the CLSI micro dilution broth
technique. The results obtained from MIC, MBC and DAD
of the pneumococcal isolate and the reference strain are
listed in Table 1.
Murine pneumonia model
Administration of AMP in combination with AZM re-
sulted in a significant reduction of colony-forming units
in lungs from 2 to 6 hours, and in blood it was between 2-
4 hours post antibiotic treatment compared with non-
treated infected animals. In addition, the lungs of mice
treated concomitantly with AMP and AZM at 18 hours
post infection had fewer S. pneumoniae organisms on 3, 4,
5 and 6 hours, respectively, after antibiotic treatment than
those of mice treated with AMP or AZM alone (Table 2).
Table 2 also shows the changes in bacterial density in
the lungs and blood of mice after infection with AMRI-
SP1. Infected mice developed bacteremia within 24 hours
of infection. The numbers of viable cells of AMRI-SP1 in
the lungs and blood of untreated infected mice showed
significant gradual increase in blood, up to 24 hours after
infection, and their numbers also increased in lungs. Ad-
ministration of AMP or AZM alone to infected animals
significantly reduced bacterial counts in lungs and blood
with time.
Pharmacokinetics (PK) and pharmacodynamics (PD) of the
drugs
Following a single intravenous bolus administration of
AMP (200 mg/kg body weight) and AZM (50 mg/kg
body weight), the PK and PD values obtained in the
serum of mice infected with S. pneumoniae AMRI-SP1
is shown in Table 3.
Therapeutic efficacy of AMP and AZM combination
against mortality in experimental pneumococcal
pneumonia
Inoculation of mice with 106 CFU of S. pneumonia
(AMRI SP-1) resulted in 100% mortality in untreated
Table 1 In vitro susceptibilities of Streptococcus pneumoniae strains to different antimicrobial agents*
Drug MIC (mg/L) MBC (mg/L) Zone diameter (mm)
ATCC 49619 AMRI SP 1 ATCC 49619 AMRI SP 1 ATCC 49619 AMRI SP 1
PEN 0.06a 64b 0.06 - 26 +
AMP 0.25a >32b 0.5 - 20 +
AZM 0.12a 8b 2 16 23 10
AMC 0.06a 2a 0.12 8 24 22
OXA 0.06a 0.25a 0.25 0.5 23 22
CAZ 8c 16b 16 >64 23 15
CRO 1a 2b 4 4 22 16
CTX 4a 0.5a 8 1 23 22
CXM 0.5a 2a 1 64 25 23
FEP 0.06a 0.5a 0.06 1 25 24
CLI 0.5a 4b 0.5 16 17 13
IPM 0.06a 0.12a 0.12 1 23 25
MEM 0.06a 0.06a 0.12 1 24 24
LVX 0.12a 16b 0.12 32 19 12
CIP 0.06a 1a 0.12 2 23 25
RIF 0.06a 0.12a 0.12 1 20 21
VAN 1a >64b 4 - 19 +
GEN 0.5a 2 1 4 23 20
TMP-SXT 1a >64b 2 - 18 +
*PEN- Penicillin, AMP- Ampicillin, AZM- Azithromycin, AMC- Amoxicillin/Potassium Clavulanate, OXA- Oxacillin, CAZ- Ceftazidime, CRO- Ceftriaxone, CTX- Cefotaxime,
CXM- Cefuroxime, CLI- Clindamycin, IPM- Imipenem, MEM- Meropenem, LVX- Levofloxacin, CIP- Ciprofloxacin, RIF- Rifampin, VAN- Vancomycin, GEN- Gentamicin,
TMP-SXT- Trimethoprim/Sulphamethoxazole.
‘-‘Not within the detectable limit; ‘+’ No zone of inhibition detected.
aSensitive, b: Resistant, c: Intermediate.
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ministered at 200 mg/kg body weight at 18 hours post in-
fection was associated with ~40% survival rates where as
therapy with AZM alone at 50 mg/kg body weight initi-
ated at same time resulted in ~60% survival rate. Further-
more, treatment with both the antibiotics was associated
with ~80 – 90% survival rates. (P < 0.05).
Lung tissue myeloperoxidase (MPO) enzyme activity
The activity of MPO enzyme which is an indicator for
neutrophil infiltration and the highest levels of lung
MPO in infected animals appeared at 6 h. When AMP
or AZM were administered alone or in combination, it
caused significant (P < 0.05) time dependent reduction in
tissue MPO enzyme activity than that of non-treated
AMRI-SP1 infected mice (Figure 2).
Pulmonary vascular permeability
The pulmonary vascular permeability (as evaluated by
Evans blue extravasations) showed higher values (P < 0.05)
in S. pneumoniae infected untreated mice which was de-
creased gradually after treatment of AZM alone or in
combination with AMP at 3,4,5 and 6 hours post anti-
biotic treatment (Figure 3).Cytokine (IL-6, IL-10, IFN-γ and TNF-α) levels in serum
after treatment with combined antibiotics in AMRI-SP-1
induced experimental pneumonia
Serum TNF-α, IFN-γ, and IL-6 levels but not IL-10 was in-
creased significantly after S. pneumonia infection (P < 0.05).
Treatment of mice with either AMP or AZM alone or in
combination after infection was able to significantly down
regulate the serum TNF- α, IFN- γ and IL-6 levels at 2, 3,
4, 5 and 6 hours post antibiotic treatment. However, AMP
in combination with AZM also increased the serum IL-10
level after 3, 4, 5 and 6 hour post initiation of therapy than
that of AMP or AZM alone (Figure 4; A: IL-6; B: IL-10; C:
IFN-γ and D: TNF-α).
Cytokine (IL-6, IL-10, IFN-γ and TNF-α) levels in lung
homogenates after treatment with combined antibiotics
in AMRI-SP-1 induced pneumonia
As correlates of antibiotic treatment–mediated pulmonary
inflammation, levels of cytokines in lung homogenates
were measured. An increase in the levels of cytokines par-
ticularly TNF-α and IL-6 was seen in the lungs of AMP
treated mice initiated 18 hours after S pneumonia infec-
tion, and was reduced after initiation of treatment with
AZM alone or in combination with AMP. However, the
Table 2 Bacterial burden in lungs and blood of mice infected with S. pneumoniaea and receiving either a single or a
combined antibiotic treatment
Treatment Collection of samples at





CFU (Mean ± SD)
Lungs (per ml of tissue homogenate) Blood (per ml)
Untreated 0 4/0 114 ± 10.26 29 ± 9.34
1 4/0 186 ± 12.04 38 ± 8.33
2 4/1 290 ± 8.48 134 ± 10.06
3 5/2 356 ± 15.23 182 ± 13.65
4 6/3 408 ± 7.36 242 ± 15.27
5 6/4 468 ± 11.45 286 ± 10.14
6 6/6 480 ± 5.76 307 ± 10.58
AMP alone 0 4/0 390 ± 17.43 16 ± 5.66
1 5/0 338 ± 15.27 24 ± 5.06
2 5/0 307 ± 10.58 42 ± 8.19
3 5/2 286 ± 10.14 186 ± 4.58
4 5/3 242 ± 15.27 196 ± 8.50
5 6/3 182 ± 13.65 143 ± 9.53
6 6/4 134 ± 10.06 111 ± 3.05
AZM alone 0 4/0 376 ± 7.05 56 ± 6.28
1 4/0 342 ± 11.59 71 ± 11.25
2 4/0 311 ± 14.36 83 ± 10.09
3 4/2 262 ± 9.53 162 ± 11.59
4 5/3 196 ± 4.58 134 ± 6.02
5 6/2 143 ± 8.50 104 ± 7.58
6 6/2 111 ± 3.05 95 ± 3.51
AMP + AZM combined 0 4/0 381 ± 3.51
1 4/0 356 ± 9.60 89 ± 7.26
2 4/1 324 ± 7.36 90 ± 12.03
3 5/1 252 ± 4 175 ± 8.79
4 6/1 173 ± 7.37 131 ± 6.82*
5 6/0 137 ± 6.02 79 ± 5.36*
6 6/0 99 ± 1.52 44 ± 10.15
a5 × 106 CFU/mouse; cSignificant difference (P < 0.05) compared with the results for untreated S. pneumoniae infected group. Mean bacterial counts in lungs and
blood at 18 h post infection for mice infected with S. pneumonia (AMRI-SP-1) and after initiation of antibiotic therapy either alone or in combination. *Bacterial
CFU counts in the AMP + AZM group are significantly lower than that of AMP or AZM alone groups at 4th and 5th hour post antibiotic treatment. Results for each
group are given as mean ± standard deviation of five mice.
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http://www.journal-inflammation.com/content/11/1/5lung IFN-γ was decreased at 2 hours after initiation of
AMP or AZM alone or in combination, when compared
to untreated S. pneumonia infected mice. Conversely, the
level lung IL-10 were increased starting at 2 hours after
initiation of AZM alone or in AMP plus AZM treated
mice and sustained up to 6 hr post antibiotic treatment
when compared to S. pneumonia infected untreated group
(Figure 5; A: IL-6; B: IL-10; C: TNF-α and D: IFN-γ).
Effect of AMP and AZM treatment on lung tissue
Cyclooxygenase-2 level in the S. pneumoniae infected mice
Immunoblot analysis of lung tissue homogenate showed
that COX-2 level was significantly increased at 18 hourspost-infection in case of the S. pneumonia AMRI-SP-1,
which was gradually decreased at 2-4th hrs of post anti-
biotic treatment. After treatment with ampicillin along
with AZM, cox-2 level was decreased at 4th hour of anti-
biotic treatment (Figure 6).
Estimation of inflammatory cells in BALF
Leukocyte recruitment to alveoli was determined in the
BALF. Compared to S. pneumoniae infected untreated
control group of mice that received antibiotic therapy either
alone or in combination exhibited steady drop in PMN
counts in BALF at every time point of the experiment. Fur-
thermore combination therapy was more effective in down
Table 3 Pharmacokinetic and pharmacodynamic
parametersa for ampicillin (AMP) and azithromycin (AZM)
following a single intravenously administered dose of
both drugs 18 h post infection
Parameters
(Mean ± SD) Ampicillin Azithromycin
Pharmacokinetics
Dose (mg/kg) 200 50
Cmax (μg/ml) 4586 ± 22.3 8.9 ± 0.26
Cmin (μg/ml) 16.25 ± 0.9 2.1 ± 0.18
AUC0-6 (μg.h/ml) 111265 ± 14610 15310 ± 1215.86
t1/2 (h) 0.963 ± 0.03 16.5 ± 1.56
Ke (h
−1) 0.057 ± 0.013 0.19 ± 0.002
Pharmacodynamics
AUC/MIC (h) 3477.03 32.24
T > MIC (h) 6.741 5.1
Cmax/MIC 143.31 1.11
aAbbreviations: Cmax maximum concentration of drug in serum, Cmin minimum
concentration of the drug in serum, t1/2 time taken to reach half of the
maximum concentration, AUC area under the concentration-time curve from
time zero to 6 h post antibiotic treatment, Ke- Elimination rate of the drug,
T>MIC Time during which the drug concentration remains above the MIC value
in serum, AUC/MIC Ratio of area under the curve during 6 h of post antibiotic
treatment to the MIC value for the S. pneumoniae strain AMRI-SP1, Cmax/MIC ratio
of maximum concentration of the drug achieved in serum to MIC of the drug.
Figure 2 MPO activity of lung tissue of mice after intranasal
administration of S. pneumoniae (AMRI-SP 1) followed by
treatment with ampicillin or azithromycin alone or in
combination. MPO activity was analyzed as index of neutrophil
infiltration in the lung tissue. The rate of change in absorbance was
measured spectrophotometrically at 405 nm. MPO activity has been
defined as the concentration of enzyme degrading 1 μM of
peroxide/min at 37°C and was expressed as change in absorbance/
min. mg of protein. The results were reproduced in three repeated
experiments. Data are expressed as mean ± SD of mice per group.
P value less than 0.05 was considered as significant. *Significant
decrease and #Significant increase at P < 0.05 level.
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decrease in PMN recruitment occurred from 3 hours after
initiation of therapy which corresponds to a gradual cure
from bacterial invasion. As for the monocyte/macrophage
recruitment in alveoli (BALF), a gradual increase was
noted in untreated infected mice. A significant reductionFigure 1 Effect of combined antibiotic treatment on the
survival of mice infected with S. pneumoniae (AMRI SP-1). Mice
were challenged with a low dose of S. pneumoniae (5×106 CFU/mouse).
Infected mice were treated with either AMP or AZM only or both in
combination, 18 hours after infection (arrow: treatment regimen). The
results (P < 0.05) of the survival analysis for groups of S. pneumoniae
infected mice receiving either sterile saline (infected control) or
antibiotic (n = 12 mice per experimental group and treatment regimen
are indicated). AMP: Ampicillin treated; AZM: Azithromycin treated;
Combination: AMP + AZM treated).in those cell counts was observed at 3 hours to 6 hours
after initiation of treatment compared to either of the an-
tibiotics alone (Figure 7).
Lung histopathology
To investigate the histopathological changes underlying
S. pneumoniae induced experimental pneumonia in mice
lungs and subsequent recovery from this disease state
using combination therapy with AMP and AZM, ani-
mals were intranasally challenged with AMRI SP-1 andFigure 3 Lung vascular permeability measurement. Pulmonary
vascular permeability in S. pneumoniae infected groups (mean ± SD
for five mice). The results were reproduced in three repeated
experiments. Data are expressed as mean ± SD of mice per group.
P value less than 0.05 was considered as significant. *Significant
decrease and #Significant increase at P < 0.05 level. *, SP infected vs.
AZM alone; significant decrease at 3, 4, 5 and 6 hour, SP infected vs.
AMP + AZM combined; significant decrease at 3,4,5 and 6 hour, SP
infected + AZM vs. Sp infected + AMP + AZM; Significant decrease at
3,4,5 and 6 hour.
Figure 4 Serum levels of IL-6 (A), IL-10 (B), IFN-γ (C), and TNF-α (D) in different groups of mice at 0 to 6 h post antibiotic treatment.
Levels of IL-6 (A), IL-10 (B), IFN-γ (C), and TNF-α (D), in serum from S. pneumoniae infected mice untreated or treated with ampicillin (AMP) or
azithromycin (AZM) alone or in combination after 18 h post infection were determined by utilizing ELISA according to the manufacturer’s
recommendations and were expressed from triplicate experiments. AMRI SP-1 infected animal which were left untreated was considered as
control while comparing with those treated AMP or AZM or both. A significant increase in TNF-α, IFN-γ, and IL-6 but decrease in IL-10, *P < 0.05
was observed after 1 h of post antibiotic treatment; S. pneumoniae isolate AMRI SP-1 alone, versus S. pneumoniae AMRI SP-1, + AMP, significant
decrease in TNF - α, IFN-γ and increased IL-10, #P < 0.05, S. pneumoniae AMRI SP-1 alone, versus S. pneumoniae AMRI SP-1 + AMP + AZM showed
significant decrease in TNF-α, IFN-γ and significant increase in IL-10 following 1 h post antibiotic treatment, #P < 0.05.
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shows normal lung histology of mice at low and high
magnification. The sections of normal lungs shows alveoli
are composed of a single layer of squamous epithelium,
bronchioles are lined by ciliated columnar epithelium (lar-
ger bronchioles) or cuboidal epithelium (smaller bronchi-
oles leading to alveoli). Between the alveoli a thin layer of
connective tissue and numerous capillaries also lined with
simple squamous epithelium.
Figure 8(B) shows lung histology of mice infected with
AMRI SP-1 at 18 hours post infection at low and high
magnification. At low magnification a patchy area of
alveoli that are filled with inflammatory cells are seen.
The alveolar structure is still maintained, which is why
pneumonia often resolves with minimal residual destruction
or damage to the lung. At high magnification the alveolar
exudates of mainly neutrophils is seen. The surrounding
alveolar walls have capillaries that are dilated and filled
with RBCs.
Figure 8(C) shows lung histology as a result of treat-
ment with AMP at low and high magnification. Destruc-
tion of lung tissue and haemorhage associated with the
accumulation of more number of inflammatory cells arevisible. At higher magnification, early abscessing pneu-
monia was observed. Alveolar walls are not clearly seen
only sheets of neutrophils are visible.
Figure 8(D) shows histological changes in lungs of
mice treated with AZM at low and high magnification.
Representative lung histology demonstrates that AZM
treatment led to persistent lung infection with extensive
granulomas and peribronchiolar inflammation.
Figure 8(E) shows histological changes in lungs of
mice treated with AMP and AZM in combination at low
and high magnification. Animals treated with both the
drugs recovered very fast and had tissue profiles similar
to those of healthy controls. Since the combined drugs
were administered once, few residual inflammatory cells
were observed after therapy.
Discussion
Approaches have been made to find new targets for anti-
microbial activity, use of combination agents that are ef-
fective against more than one target in the cell, or new
delivery mechanisms to maximize the concentration of
antimicrobial agents at the site of infection, but relevant
clinical evidence with respect to combining agents, has
Figure 5 Cytokine level in lung tissue. Groups of mice (n = 21) were infected with AMRI-SP1 and were monitored for the development of
pneumonia. 18 h post infection treatment with either AMP at 200 mg/kg or AZM at 50 mg/kg body weight, single dose of antibiotic treatment
was initiated. Considering 18th h to be the zero hour of antibiotic treatment, animals were sacrificed every hour continuing till 24th h post infection
(i.e. 6th hour post antibiotic treatment). After administration of the single antibiotic dose, lungs were homogenized and assayed for estimation
of cytokines. Levels of IL-6 (A); IL-10 (B); TNF-α (C) and IFN-γ (D) were determined and mean ± SD of values obtained were expressed in pg/ml
from triplicate experiments. Untreated, S. pneumoniae infected; AMP, S. pneumoniae infected and treated with ampicillin; AZM, S. pneumoniae
infected and treated with azithromycin; Combined, S .pneumoniae infected and treated with both ampicillin and azithromycin. #, Significant
increase or *, Significant decrease in combined treatment group compared to monotherapy with AMP or AZM alone at P < 0.05.
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strains. Given the astronomical costs involved in the re-
search and development of a new drug and also the time
required to take it from ‘the bench to the bedside’,
utilization of combination therapy using known antibi-
otics should be a preferred as a cost-effective choice for
therapy. In the current study we have used a murine
pneumococcal pneumonia model to compare the effi-
cacy of monotherapy with combination therapy by ad-
ministering a single intravenous dose of AMP and AZM.
From the bacterial growth and magnitude of inflamma-
tion (leukocyte infiltration into the lungs, lung cox-2
and high pulmonary vascular permeability) observed in
our case supported the mouse model of pneumococcal
pneumonia.
Use of β-lactam agents such as AMP, may increase and
complicate the problem because these agents lyse the bac-
terial cell wall leading to release of proinflammatory sub-
stances such as cell wall components and cytotoxins
which are recognized by the innate immune system and
which trigger the inflammatory response [42,43]. It wasobserved that macrolides (erythromycin) and macrolide-
like agents (AZM, clindamycin, telithromycin), at sub-
MIC concentrations, were potent inhibitors of pneumoly-
sin production by both susceptible and resistant strains of
Streptococcus pneumoniae, with doxycycline being some-
what less effective, while amoxicillin, ceftriaxone, and
tobramycin were ineffective. AZM alone is unlikely to
be preferred as resistance rates of community isolates of
S. pneumoniae are high [44]. But owing to its anti-
inflammatory effects and broader spectrum of activity it
might be a realistic candidate [45-48]. In addition AZM
retained its anti-inflammatory activity against a resistant
strain when used in combination therapy. This finding
suggests that there might be clinical benefit independ-
ent of antibiotic susceptibility pattern [29].
Azithromycin (AZM) and ampicillin (AMP) in combin-
ation against an azithromycin resistant strain was reported
to cure secondary pneumonia in mice. Thus we choose
AZM and AMP as combinatorial antibiotic therapy even
though we found the S. pneumoniae (AMRI-SP-1) was resist-
ant to AMP or AZM applied in single doses. Furthermore,
Figure 6 Expression of COX-2 after treatment with ampicillin in
combination with azithromycin in lung tissue. Expression of
COX-2 in lung tissue was measured in terms of fold change over S.
pneumoniae infected untreated control. Highest level of COX-2 was
found at 18 h post infection. Gradual reduction in COX-2 level was
visible after treatment with ampicllin in combination with azithromycin
with the decrease being most prominent at 4th hour post antibiotic
treatment. S. pneumoniae AMRI SP -1 infected untreated control group
versus S. pneumoniae AMRI SP-1 + ampicillin + azithromycin treated
group (P < 0.01 significant decrease with respect to SP infected
untreated control at 1-3 h post antibiotic treatment).
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pneumococcal pneumonia, the lowest survival rate in
antibiotic-treated animals was observed in those treated
with AMP only, while the highest rates were noted in
those treated with inhibitors of protein synthesis (AZM or
clindamycin) only, or in combination with AMP [49]. Im-
proved survival with AZM was associated with an attenu-
ated inflammatory response, manifested as lower numbers
of inflammatory cells and pro-inflammatory cytokines inFigure 7 Mean (± SD) neutrophil (A) and monocytes (B) counts in BAL
at 50 mg/kg body weight. *Significant decreases in both cell populations
combination therapy, which was started after 18 hours post infection. *, P <the lungs, and less severe histopathological changes.
Therefore, antibiotic selection based solely on the grounds
of antimicrobial potency may be inappropriate in some
clinical settings, particularly serious infections caused by
toxin-producing pathogens with high bacterial loads [50].
In this situation, circumstances permitting, administration
of an inhibitor of bacterial protein synthesis, either prior
to, or together with a compatible bactericidal agent may
be justified to reduce the potential risk of an antibiotic-
associated inflammatory reaction. Based on laboratory, ex-
perimental animal, and limited clinical data, potential
strategies to address this complex clinical problem include
combining an inhibitor of bacterial protein synthesis
(preferably one with secondary anti-inflammatory proper-
ties, i.e. a macrolide), with a cell-wall active agent. Thus,
our choice of AMP along with AZM as combinatorial
therapy against the multi-drug resistant S. pneumoniae
(AMRI-SP-1) in this mouse model of pulmonary infection
was hypothesized to be an effective combination therapy.
AZM exhibits anti-inflammatory activities independent of
its antimicrobial properties [51]. This antibiotic resulted
in clinical cure in S. pneumonia infected mice, although it
is unclear whether the improved outcomes are solely the
result of the mechanism of action or whether they are the
result of this factor in addition to the anti-inflammatory
properties of the drug [49]. The exact mechanisms of ac-
tion for the macrolides like azithromycin that have this
anti-inflammatory action are still not completely defined,
although it is known that they act by various molecular,
cellular, and bacterial mechanisms. It might be due to de-
creased chemotaxis, migration, and cellular activity in
neutrophils and macrophages and concomitant decrease
in IL-6, TNF-α, IFN-γ and PGE2 in the air way passages
after azithromycin administration.
Determining the drug levels in serum as a function of
time is essential for estimating the concentration of the
antibiotic that are necessary to inhibit (MIC) or to be
bactericidal (MBC) to microorganisms. Drug concentrationF of infected mice, treated with AMP at 200 mg/kg and/or AZM
were seen by 3 hours in (A) and 2 hours in (B) after initiation of
0.05.
Figure 8 (See legend on next page.)
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Figure 8 Histology of lung tissue in normal mice (A); S. pneumoniae infected mice (B); treated with antibiotics ampicillin (AMP) (C) and/
or azithromycin (AZM) (D) either alone or in combination (E) 18 hours post infection. Pictures were taken from 0 – 6 hours after initiation
of therapy which corresponds to 18 – 24 hours post infection. Profuse neutrophil count, diffuse edema with swelling of interstitium was noted in
untreated infected animals, while mice receiving combination therapy recovered very fast than monotherapy and had tissue profiles similar to
those of healthy controls. Left panel shows histology of lung tissue at low magnification and right panel at high magnification. Arrow indicates
accumulation of PMNs in the alveoli.
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bacterial eradication. β- lactam antibiotics such as AMP are
unevenly distributed in tissue, with a tissue: serum ratio <
1:1 for most sites. They are distributed mostly in the blood
and extracellular fluid that represents about 20% of the total
body mass. Conversely macrolides have high tissue: serum
ratios (> 2:1) and are found predominantly inside cells.
Concentrations of these drugs are therefore lower extracel-
lularly while concentrations of β-lactams are higher [52].
AMP has been known to exhibit-time dependent killing
which means a long time above MIC (T >MIC) or a large
ratio of area under the curve (AUC) to MIC (AUC/MIC) is
predictive of a successful treatment outcome [53]. Concen-
tration dependent drugs like AZM are characterized by a
steeper pharmacodynamic (PD) function; the steeper the
PD function, the more efficient is the bacterial killing which
increases commensurately with antibiotic concentration.
The PK and PD parameters suggest that ampicillin
was widely distributed in the extracellular fluid and into
tissues. A rapid distribution of the drug between blood
and the extravascular tissue compartment was achieved
which was consistent with that found in the literature.
Azithromycin remained in circulation for a longer dur-
ation and was available in the tissue bed or at the site
of infection thus exerting its bactericidal and anti-
inflammatory effect there. It was reported that amoxicil-
lin (AMX), a β-lactam antibiotic, was able to clear the
infection of two resistant pneumococci (MICs 1 and
2 μg/ml) if the dose was increased [53]. However, in a
mouse pneumonia model, significant bactericidal effect
was not achieved on penicillin resistant pneumococci
strains for which the MIC was ≥ 2 mg/L, even with a
dose/MIC ratio of 200 [50]. In another study with peni-
cillin resistant pneumococci strain (MIC 4 mg/L), a kill-
ing of 2 to 3 log10 within the first 6 h was observed,
independent of Cmax ranging from 2 to 20 times the
MIC. Regrowth occurred after 12 h in a majority of the
experiments [54]. Thus an increased Cmax and larger
AUC were not sufficient to achieve a predictable killing
for that strain. The findings from our present study also
supports this observation that AMP though adminis-
tered at a 4 times greater dose compared to AZM,
achieved a greater Cmax and AUC but was not effective
in clearing the bacterial load from the lungs in group of
mice treated with AMP alone. So the need for studying
highly resistant pneumococci is paramount to seek anexplanation for this observation and determine its
prevalence.
Macrolides induce a biphasic effect on the host. First,
they have direct antimicrobial activity by stimulating the
host defense against bacteria via stimulation of leukocyte
degranulation, phagocytosis and oxidative burst. Sec-
ondly, after the acute infection, neutrophils that are
primed by cytokines or pneumolysin are inhibited by
macrolides, that leads to amelioration of the inflamma-
tory response. Another potential explanation for the
beneficial effects of macrolides is reduction in bacterial
load with less cell wall lysis than beta-lactam antibiotics;
this results in a more gradual reduction in bacterial load
and, therefore, a more gradual release of immunologic-
ally reactive components, which may prevent an ex-
tended systemic inflammatory response [55]. In our
study, changes in bacterial density in lung for AMP or
AZM monotherapy were similar against S. pneumoniae
isolate. For the AMP +AZM combination regimens, we
found changes in lung bacterial density to be greater
compared with AMP or AZM monotherapy for AMRI-
SP-1. Clearance of bacteria from blood also increased
after combined antibiotic therapy than the AMP or
AZM alone at 3 h after initiation of antibiotic therapy.
Therefore, it may be suggested that the outcome in
pneumococcal pneumonia was improved when combin-
ation antibiotic therapy was initiated at early stages of S.
pneumoniae infection even when the bacteria was resist-
ant to that antibiotic [16,17].
Subsequently, we determined whether neutrophils
were critical for combined antibiotic-mediated protec-
tion in the pneumococcal infection. Animals infected
with S. pneumoniae and 24 h later that were remained
untreated showed heavy infiltration of PMN affecting
the lung inflammation. However, co-administration of
AMP and AZM after the pneumococcal challenge led to
reduced PMN infiltration in lungs.
The timing of the observed decrease in neutrophil
numbers and inflammatory mediators argues against a
causal link between decreased inflammation and host
protection. Specifically, combined antibiotic treatment
reduced the pulmonary bacterial burden as early as at
2 h after initiation of antibiotic treatment, whereas the
decreased inflammatory response was also apparent until
6 h post antibiotic treatment. In addition to this discrep-
ancy in timing, there is substantial evidence that the
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flammatory mediators are protective against S. pneumoniae-
induced mortality.
High IL-6 concentrations were found in the lungs of
mice infected with SP. In addition relatively higher
serum IL-6 levels has been reported after intravenous in-
jection of wild type SP than after administration of
pneumolysin (PLY) negative mutant SP suggesting the
induction of an inflammatory response in the pulmonary
compartment in the early phase of pneumococcal pneu-
monia [56]. During lung inflammation in acute phase,
damaged alveolar capillary and epithelial membranes by
PMN leading to leakage of protein rich edema fluid into
the alveolar space, and formation of hyaline membranes
which impaired gas exchange have been reported [57].
At early stages of infection the permeability of lung vas-
culature is increased due to enhanced release of proin-
flammatory cytokines (TNF-α, IFN-γ and IL-6) [58-60].
Hence, decrease in extravasations after initiation of com-
bined antibiotic therapy after 3 h of post antibiotic treat-
ment may be due to reduced lung TNF-α, IFN-γ and IL-6
level and increased anti-inflammatory cytokine (IL-10),
which is sustained until 6 hours post antibiotic treatment.
The inflammatory cytokine response in the lung is
characterized by intense elevation IL-6, TNF-α and IFN-
γ which was decreased after combined treatment. A sub-
sequent increase in IL-10 after combinatorial treatment,
which is an anti-inflammatory cytokine that inhibits
macrophage and neutrophil production, is the beginning
of the anti-inflammatory response that prevents an un-
controlled inflammatory response. IL-6 has been consid-
ered as a marker for the severity of bacterial challenge
represents a relevant marker for the evolution of a host
response and high IL-6 concentrations have been found
in the lungs of mice infected with SP [61]. Therefore, re-
duced IL-6 in combined antibiotic treated mice might be
responsible for decreased inflammation in mouse lungs
along with reduced lung TNF-α and IFN-γ after antibiotic
treatment.
We observed that IFN-γ, TNF-α, IL-6 but not IL-10
production was increased initially 18 hours post-
infection and decreased gradually thereafter following
treatments with AMP and AZM. Therefore, it is likely
that increased TNF-α and IFN-γ released into the circu-
lation after infection by the administration of S. pneumo-
nia cells or their exotoxins demonstrated a detrimental
effect on the host. We found that severity of pneumonia
is associated with altered balance of inflammatory cyto-
kines, and conversely, altering the balance of inflamma-
tory cytokines has a significant impact on the severity of
pneumococcal pneumonia. It was reported that azithro-
mycin at concentrations of 1, 5 and 10 μg/ml have been
demonstrated to affect in various degree of production
of IL-1, IL-6 and IL-10, GMCSF and TNF-α by humanmonocytes. Most remarkably, azithromycin resulted in a
significant decrease of TNF-α in 100% of individuals and
treatment with clarithromycin resulted in a significant
decrease in IL-6 and TNF-α in 86% of individuals re-
spectively [62,63].
Of several pneumococcal pneumonia-related molecu-
lar pathways with anti-inflammatory actions, we chose
to focus on IL-10 as a representative of cytokine in this
class. IL-10 appears to be valuable for attenuating in-
flammatory damage to human lung [64]. Since serum
cytokines were considered as a reflection of inflamma-
tion induced by pathogens anti-inflammatory cytokines
like IL- 10 continues to increase even at 6 hours after
treatment of mice with AMP and AZM. This IL-10 level
increment dictates the resolution of inflammation and
may be a positive prognostic indicator for recovery of
pneumonia due to the combined therapy. IL-10 inhibits
the production of reactive oxygen and reactive nitrogen
intermediates when monocyte and macrophages are ac-
tivated by IFN-γ and therefore may be important in de-
termining the outcome of pneumonia. As lack of IL-10
causes impaired clearance of bacteria leading to a more
destructive cause of pneumonia, therefore, this elevated
IL-10 in the combined antibiotic treated mice might be
essential for efficient elimination of bacteria and therapy
for protection against pneumococcal pneumonia. IL-10
is often considered as the master regulator in immunity
from infection [65]. IL-10 reduces both the extent and
the duration of inflammation, the outgrowth of pneumo-
cocci, and mortality [66].
Therefore, the present finding indicated that in the pres-
ence of concurrent treatment with AMP+AZM may lead
to elevated circulating IL-10 that might influence bacterial
outgrowth, suggesting that only in the latter phases of
pneumococcal pneumonia is IL-10 essential for host
defense. It was reported that IL-10 given at latter stages of
infection prevented severe inflammation and lung edema
and facilitated bacterial clearance in mice treated with cef-
triaxone [66]. However, whether elevated systemic IL-10
during combined therapy could modulate the blood and
lung levels of antibiotics [67], either AMP or AZM have
not been tested in our case. Previous data also indicated a
beneficial role for IL-10 as an adjunctive therapy to antibi-
otics against pneumococcal pneumonia in mouse model
[66]. These protective effects might have resulted from de-
creased pulmonary inflammation and better availability of
the drug to the infected sites. Better bacterial clearance
was also reported in other in vivo studies with IL-10 [68].
Immunoblot analysis of lung tissue homogenate showed
that COX-2 level was significantly increased at 18 h post-
infection in case of the S. pneumonia (AMRI-SP1), which
was gradually decreased at 1, 2, 3 and 4 h post antibiotic
treatment. After treatment with AMP along with azithro-
mycin, COX-2 level was significantly decreased on 4 h
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oxide, TNF-α, and IL-6 levels has been previously re-
ported in murine macrophages treated with 5 to 80 μM
of azithromycin [46]. Given its constitutively expressed
nature and predominant role in prostaglandin synthesis
during bacterial infection, potential strategies for drug
resistant bacteria based on COX pathways or inhibiting
COX-2 [69]. These data collectively support that com-
binatorial antibiotic treatment mediated COX-2 inhib-
ition or strategies that disrupt prostaglandin signaling
pathways as useful adjunctive therapies in treating per-
sistent and multi-drug resistant infection.
The combined antibiotic therapy promoted the infiltra-
tion of peripherally circulating neutrophils into the lungs,
leading to bacterial clearance, COX-2 pathway in lungs
and the lung cytokines might determine the outcome of
interactions with microbes in the lungs. Insights into the
functional roles of cytokines, and regulatory factors in me-
diating pulmonary immune responses may contribute to
rationally designing and appropriately using therapeutic
and prophylactic agents. This basic study may be consid-
ered for strategies aimed at altering leukocyte recruitment,
bacterial clearance and pulmonary inflammation in order
to improve host defense (e.g. against antibiotic-resistant
organisms).
Conclusion
These data indicated a beneficial role for AMP and AZM
as combinatorial therapy against pneumococcal pneumo-
nia. Inflammation mediated by bacterial toxins on lysis of
the cells due to exposure to cell wall active agents might
be reduced with this mode of therapy in penicillin and
macrolide resistant isolates also as evident from our find-
ings, irrespective of their antimicrobial susceptibility pat-
tern in in vitro conditions. Thus macrolides specifically
azithromycin can be still used in combination with cell-
wall active agents such as ampicillin in treatment of S.
pneumoniae infections due to a resistant organism.
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